March is National Sleep Awareness Month, and nighttime itching is known to keep families affected by atopic dermatitis (AD) up at night. Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the results of a new Dermavant survey of 502 adults with AD and 510 caregivers of kids with AD that showed sleep disruptions caused by itching negatively impact mood, productivity, and stress levels. “Asking about the presence and severity of itch and sleep disruptions can be extraordinarily powerful,” he says in an exclusive interview with TDD. “Without that information you may not be able to choose the right treatment for the right patient and address all of their symptoms.” More information on the sleep survey is available here. Dermavant submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older.
